Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Risk premia -
Unfortunately they have, significantly.
There is low liquidity in the MNTA jan 11 leaps = wide spreads. May be cheaper to buy the nearbys and roll them.
Why not consider options for a binary stock like MNTA? With the Jun 10's you get a delta of .67 for less than one fifth of the price. Chances of losing everything are the same as a direct buy, but you lose a lot less.
I thought he was being ironic, but he was serious? Really?
I'm getting an AVIRA virus warning when accessing Biotech Values from Firefox, but not from Internet explorer. Daily scans do not reveal an infection. Is anybody else getting this warning? Thanks.
Apples and oranges, I know, but ironic nonetheless.
SRT501 is our proprietary formulation of resveratrol with improved bioavailability. In Phase I human clinical trials, SRT501 was found to be safe and well tolerated. In Phase IIa human clinical trials, SRT501 also lowered glucose and improved insulin sensitivity in patients with Type 2 Diabetes. We are currently testing SRT501 in a Phase IIa trial in cancer.
The patents may be immaterial to CYCC's current activities, but it would seem they are of value to CELG. That is something that might be monetized.
This is months old and may have been posted here. If so, apologies for wasting space:
>>OGD’s ANDA Backlog and Median ANDA Approval Times are Up – WAY UP! “The Solution Lies in Resources,” Says FDA Commissioner Hamburg
By Kurt R. Karst –
FDA’s Office of Generic Drugs (“OGD”) has a backlog of Abbreviated New Drug Applications (“ANDAs”) that is nearing 2,000, according to OGD Director Gary Buehler, who presented the data at the recent Generic Pharmaceutical Association (“GPhA”) Annual Meeting. OGD’s median ANDA approval time was also up about 5 months – to 26.70 months – in Fiscal Year (“FY”) 2009 compared to the FY 2008 figure of 21.65 months. Both the ANDA backlog and median approval times have progressively increased over the past several years, while the numbers of ANDA receipts and approval actions have remained relatively steady, as illustrated in the tables below from Mr. Buehler’s GPhA presentation.
So why such a ANDA backlog and rising median approval times? The answer lies in OGD’s resources, according to FDA Commissioner Dr. Margaret Hamburg. In Her speech at the GPhA Annual Meeting, Dr. Hamburg commented that “no one benefits from a pending-application queue that will soon hit the 2,000 mark. This is simply unacceptable. . . . But the unprecedented spike in generics applications has simply outstripped our capacity to properly review, which must remain our foremost focus. The solution lies in resources.” (emphasis in original)
And “resources” means both funding from Congress and the generic drug industry, according to Dr. Hamburg:
We have already begun to use the $10 million that Congress allotted to our agency to hire 50 additional scientists to address the generics-application backlog. But without action from your industry, too—without your support for a fair system of user fees—we simply cannot achieve for the public what we otherwise could. . . . We very much want to work with you to see generic drug user fees enacted this year. Adequate and reasonable fees will be key to both more rapid review and to better surveillance.
The President’s FY 2011 budget request for the Department of Health and Human Services includes $51,545,000 in appropriations to OGD (a $10 million increase over last year) and proposes “user fees to support activities related to generic human drug reviews” (as well as new user fees for re-inspections of FDA-regulated facilities). Contingent upon the enactment of authorizing legislation, generic drug user fees would be expected to bring in an amount not to exceed $38,015,000.
According to FDA’s FY 2011 Congressional Justification, generic drug user fees would more than halve the current median approval time:
FDA will hire additional staff to support the review of [ANDAs] for generic drugs and inspections of generic drug manufacturing facilities. In the case of user fees, by the end of the first five years of the Generic Drug User Fee Program, the additional user fees will result in a complete review and response for an estimated 80 percent of applications within 12 months of receipt, other than applications excluded because of exclusivity or challenges.
Previous budget requests have proposed the establishment of generic drug user fees (along with draft performance goals); however, legislation has never gotten off the ground and negotiations between FDA and GPhA were stalled, apparently over what FDA’s performance results should be.
Dr. Hamburg expressed her hope that interested parties “can return to the negotiating table soon.” GPhA appears to be open to reengaging FDA in user fee negotiations, according to a GPhA press release.
The POZN intraday chart is weird.
The MNTA sep 15 calls are reasonably priced with an IV of around 70. 20 cent spread. Delta right around .5, so you'll get price movement if the stock moves. If it doesn't move between now and september, of course, you're out 2.25. Given a possible binary event between now and september it seems like a reasonable deal to me.
IB's option commissions are also very good - or were, since I don't use them any more. They have a good trading platform. I quit using them because their trade reporting is convoluted - I want to prove to the penny every morning, and their accrual method was confusing (to me).
They would also hold an ACH transfer for days, rather than giving immediate credit. Maybe that has changed, but I thought it was chicken poop.
I bought a few IMMU June 2.5 calls for 1.25 which seems reasonable for a stock trading at 3.65 with ASCO coming up before expiration.
Thank you, that's very helpful. I've been putting it on my screen and taking it off almost daily - now I think I'll keep it on for a while. It's an intriguing chart.
Is IMMU a cult or a real company? The Yahoo profile suggests the latter but SI has a board with a real whiff of CTIC type mentality (it's all the fault of the evil shorts). Chart is okay, maybe even suggesting a coiled spring.
The conversion of the pfd creates an overhang, don't you think? My end of day buy may turn out to have been incautious.
CYCC:
And the stock promptly tanked 10%
I did buy some at the close, having sold more during the day.
Today's CYCC is unfortunately typical. A surge to 2.97, then a slow deflation.
Those guys are good!
In this particular case it's beast. Dispense as written.
Thanks. The reason that I have a small position is because of the indications it claims to be pursuing - all quite interesting. If they succeed on any one of them it could be profitable.
The way to play it so far has been to sell any opening pop and reload as it deflates. Maybe one day it won't deflate?
Stupid posts:
Hope springs eternal within the human beast?
Except for radiation seeds, you don't mention radiation. Is there a reason?
CYCC had a nice little AACR related run on Friday afternoon - roughly 10%. Was there anything after the bell?
CYCC sometimes seems to be the target of a skilled pump and dump crowd. Since I have a small position I hope to be proven wrong this time.
I suspect if a few years QOL was the goal, watchful waiting wins in a landslide.
There's a problem.You watch and wait while a vulture sits on a dead tree limb waiting for you to decline to a point where he can pick you off. And now you have advanced disease.
No QOL to that.
MON - nice call. Must have been one hell of a CC
patients continue to demand to be treated by ISRG’s da Vinci.
Unquestionably true. da Vinci sounds so cool. Glad I didn't go down that path after having read a little more deeply,
smelly
Unquestionably actionable.
Another Phase II setting up a Phase III crash?
No matter, I may plunge tomorrow if we get a weak open.
I guess I should have written interventional procedure. I don't wish to appear cynical, but my recent experience of the annual physical was that it gave my doctor a chance to find employment for his expensive toys. Which is why I no longer have a primary care physician.
I have lived (meaning over a year) in Japan, Hong Kong, Cambodia (just for completeness, doesn't belong here) UK, France and Canada. I wasn't under the system of any of those but I necessarily was able to form an opinion of the quality of the medical systems in those countries. In my view Medicare is far and away the most generous and flexible (for the patient) of any system of socialized medicine I have come across. (And yes, I do mean that Medicare is socialized medicine.)
My only complaint about Medicare - as a taxpayer - is that it is far too generous. I know of no procedure it will not cover.
I speak from some experience since I just finished a rather lengthy series of procedures at Duke for which my total copayment came to less than $1200.
Cost of gas for my gluttonous Silverado for the 720 mile round trips to Durham probably came close.
This is troubling to me because sooner or later we are going to have to deal with the issue of rationing, and with the cost of heroic measures to keep the near-dead alive for a few extra weeks. Death panels, though I'd prefer to call them something else.
That should suggest that the active calls would have gone up in price. Did they?
Truly a Koolaid stock - last I looked there were 15% of his readers who thought the stock will open above $1.
One of the things that would make the CTIC example impractical is transaction costs. IB's lowest commission is 25 cents per contract, as far as I can see, and I don't know any lower.
So is the market, it appears.